MARITIME-HF

Official Title

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Obesity and Heart Failure

Study Purpose

To demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care on the composite endpoint of heart failure (HF) events (hospitalization for HF or urgent HF visits) or death from cardiovascular (CV) disease in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) and a body mass index (BMI) ≥ 30 kg/m2

Diagnosis

BMI ≥ 30 kg/m2 Chronic symptomatic HFpEF or HFmrEF, defined as LVEF ≥ 40% at screening or within 180 days before screening

Eligibility

Stable diet and medical treatment

Intervention

Maridebart Cafraglutide / AMG 133